Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lieven Pouillon

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Journal of Crohn'S & Colitis|January 28, 2023
Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO StudyBram Verstockt, Lieven Pouillon, Florence Ballaux, et al.
Inflammatory Bowel Diseases|October 18, 2018
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center ExperienceLieven Pouillon, Cédric Baumann, Hélène Rousseau, et al.
Expert Review of Clinical Immunology|August 18, 2018
The nocebo effect: a clinical challenge in the era of biosimilarsLieven Pouillon, Marie Socha, Beatrice Demore, et al.
Gastroenterology|June 27, 2025
Inflammation Is a Large Dataset of Heartbeats, Groceries, Night Rest, and MorePeter Bossuyt, Ignace De Nollin, Thomas De Moor, et al.
Journal of Crohn'S & Colitis|July 23, 2021
Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic TrialPeter Bossuyt, Lieven Pouillon, Sophie Claeys, et al.
BMC Gastroenterology|November 29, 2023
Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational studyRoni Weisshof, Stephan R Vavricka, Lieven Pouillon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 24, 2018
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysisLaurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, et al.
Therapeutic Advances in Gastroenterology|December 17, 2021
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continuesLaurent Peyrin-Biroulet, William J Sandborn, Remo Panaccione, et al.
Inflammatory Bowel Diseases|December 4, 2019
Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel DiseaseLieven Pouillon, Eveline Hoefkens, Veronique Verheyen, et al.
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Journal of Crohn'S & Colitis|January 28, 2023
Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO StudyBram Verstockt, Lieven Pouillon, Florence Ballaux, et al.
Inflammatory Bowel Diseases|October 18, 2018
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center ExperienceLieven Pouillon, Cédric Baumann, Hélène Rousseau, et al.
Expert Review of Clinical Immunology|August 18, 2018
The nocebo effect: a clinical challenge in the era of biosimilarsLieven Pouillon, Marie Socha, Beatrice Demore, et al.
Gastroenterology|June 27, 2025
Inflammation Is a Large Dataset of Heartbeats, Groceries, Night Rest, and MorePeter Bossuyt, Ignace De Nollin, Thomas De Moor, et al.
Journal of Crohn'S & Colitis|July 23, 2021
Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic TrialPeter Bossuyt, Lieven Pouillon, Sophie Claeys, et al.
BMC Gastroenterology|November 29, 2023
Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational studyRoni Weisshof, Stephan R Vavricka, Lieven Pouillon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 24, 2018
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysisLaurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, et al.
Therapeutic Advances in Gastroenterology|December 17, 2021
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continuesLaurent Peyrin-Biroulet, William J Sandborn, Remo Panaccione, et al.
Inflammatory Bowel Diseases|December 4, 2019
Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel DiseaseLieven Pouillon, Eveline Hoefkens, Veronique Verheyen, et al.
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Pageof 6